GSK Denmark
在场
GSK Denmark 的所有者是 GSK.
是其中之一......
- Forbes Global 2000 (#187);
- Fortune 500 Europe (#81);
- FTSE 350;
- Global Fortune 500 (#343);
- Stoxx 600.
GSK 是一家在股票代码 GSK (GB) 下上市的公司。
GSK 在 21 个国家有直接业务。GSK 拥有 22家子公司，其中包括 GSK ANZ、GSK APAC 和 GSK Austria。
涉及GSK的并购和融资。
- GSK has announced the acquisition of Aiolos Bio (公布2024一月12号).
- GSK has announced the acquisition of Bellus Health (公布2023四月19号).
- GSK has announced the acquisition of Affinivax (公布2022六月1号).
高管
查看带有其 4 名主要高管的组织结构图
GSK Denmark 搜索最多的简介
- Dominika Wiktor-Brown, General Manager
- Hemal Malde, Finance Director
- Thy Trock Andresen, Medical Director
高管在GSK变化
- Jeannie LeeJeannie Lee 将于20243月4作为 Non-Executive Director 加入公司 (新闻发布的2024二月29号).
- Wendy BeckerWendy Becker 将于202310月1作为 Non-Executive Director 加入公司 (新闻发布的2023九月28号).
创建提醒
跟踪 GSK Denmark 的高管变动
药店
GSK 拥有 1,867 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- AstraZeneca has announced the acquisition of Fusion Pharma (公布2024三月23号).
- AstraZeneca has announced the acquisition of Amolyt Pharma (公布2024三月19号).
- Frontier Medicines 刚刚宣布为 80 筹款数百万美元。 (公布2024二月27号).
药店 行业的其他推荐联系人
消息
GSK Denmark 的最新新闻稿
- New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade | GSK
- GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA | GSK
- EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments | GSK
- Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer | GSK
- GSK completes acquisition of Aiolos Bio | GSK
- GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B | GSK
- DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma | GSK
- GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration | GSK
- GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk | GSK
- GSK delivers strong 2023 performance and upgrades growth outlooks | GSK
- View more press releases Close
通过电子邮件
